Search Results - "Lee, Liam C."

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance by Park, Kang-Seo, Raffeld, Mark, Moon, Yong Wha, Xi, Liqiang, Bianco, Caterina, Pham, Trung, Lee, Liam C, Mitsudomi, Tetsuya, Yatabe, Yasushi, Okamoto, Isamu, Subramaniam, Deepa, Mok, Tony, Rosell, Rafael, Luo, Ji, Salomon, David S, Wang, Yisong, Giaccone, Giuseppe

“…The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase…”
Get full text

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status by Trigg, Ricky M., Lee, Liam C., Prokoph, Nina, Jahangiri, Leila, Reynolds, C. Patrick, Amos Burke, G. A., Probst, Nicola A., Han, Miaojun, Matthews, Jamie D., Lim, Hong Kai, Manners, Eleanor, Martinez, Sonia, Pastor, Joaquin, Blanco-Aparicio, Carmen, Merkel, Olaf, de los Fayos Alonso, Ines Garces, Kodajova, Petra, Tangermann, Simone, Högler, Sandra, Luo, Ji, Kenner, Lukas, Turner, Suzanne D.

“…Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small cell lung cancer has been reported, with the majority of acquired…”
Get full text

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma by Pucci, Perla, Lee, Liam C., Han, Miaojun, Matthews, Jamie D., Jahangiri, Leila, Schlederer, Michaela, Manners, Eleanor, Sorby-Adams, Annabel, Kaggie, Joshua, Trigg, Ricky M., Steel, Christopher, Hare, Lucy, James, Emily R., Prokoph, Nina, Ducray, Stephen P., Merkel, Olaf, Rifatbegovic, Firkret, Luo, Ji, Taschner-Mandl, Sabine, Kenner, Lukas, Burke, G. A. Amos, Turner, Suzanne D.

“…Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK -expressing malignancies including neuroblastoma, but…”
Get full text

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9 by Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Jordan, L. Smith, Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji

“…Significance Currently there are no targeted therapies for KRAS mutant cancer. Our study uncovers a critical role of the small ubiquitin-like modifier (SUMO)…”
Get full text

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival by Lee, Chih-Shia, Lee, Liam C., Yuan, Tina L., Chakka, Sirisha, Fellmann, Christof, Lowe, Scott W., Caplen, Natasha J., McCormick, Frank, Luo, Ji

“…Oncogenic mutations in the small GTPase KRAS are frequently found in human cancers, and, currently, there are no effective targeted therapies for these tumors…”
Get full text

Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study by Shao, Changxia, Ren, Yixin, Zhou, Heng, Lee, Liam C., Chen, Cai, Dettman, Elisha J., Cristescu, Razvan, Gozman, Alexander, Jin, Fan, Zhou, Wei

“…Introduction Defects in the homologous recombination repair (HRR) pathway can include mutations in BRCA1 and BRCA2 (BRCAm) and other HRR genes (HRRm). These…”
Get full text

IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma by Prokoph, Nina, Probst, Nicola A., Lee, Liam C., Monahan, Jack M., Matthews, Jamie D., Liang, Huan-Chang, Bahnsen, Klaas, Montes-Mojarro, Ivonne A., Karaca-Atabay, Elif, Sharma, Geeta G., Malik, Vikas, Larose, Hugo, Forde, Sorcha D., Ducray, Stephen P., Lobello, Cosimo, Wang, Qi, Luan, Shi-Lu, Pospíšilová, Šárka, Gambacorti-Passerini, Carlo, Burke, G. A. Amos, Pervez, Shahid, Attarbaschi, Andishe, Janíková, Andrea, Pacquement, Hélène, Landman-Parker, Judith, Lambilliotte, Anne, Schleiermacher, Gudrun, Klapper, Wolfram, Jauch, Ralf, Woessmann, Wilhelm, Vassal, Gilles, Kenner, Lukas, Merkel, Olaf, Mologni, Luca, Chiarle, Roberto, Brugières, Laurence, Geoerger, Birgit, Barbieri, Isaia, Turner, Suzanne D.

“…Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK…”
Get full text

Development of siRNA payloads to target KRAS-mutant cancer by Yuan, Tina L, Fellmann, Christof, Lee, Chih-Shia, Ritchie, Cayde D, Thapar, Vishal, Lee, Liam C, Hsu, Dennis J, Grace, Danielle, Carver, Joseph O, Zuber, Johannes, Luo, Ji, McCormick, Frank, Lowe, Scott W

“…RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must…”
Get more information

Paediatric Burkitt lymphoma patient‐derived xenografts capture disease characteristics over time and are a model for therapy by Forde, Sorcha, Matthews, Jamie D., Jahangiri, Leila, Lee, Liam C., Prokoph, Nina, Malcolm, Tim I.M., Giger, Olivier T., Bell, Natalie, Blair, Helen, O'Marcaigh, Aengus, Smith, Owen, Kenner, Lukas, Bomken, Simon, Burke, Gladstone A. A., Turner, Suzanne D.

“…Summary Burkitt lymphoma (BL) accounts for almost two‐thirds of all B‐cell non‐Hodgkin lymphoma (B‐NHL) in children and adolescents and is characterised by a…”
Get full text

Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors by Shao, Changxia, Ren, Yixin, Zhou, Heng, Chen, Cai, Dettman, Elisha J, Lee, Liam C, Cristescu, Razvan, Gozman, Alexander, Jin, Fan, Zhou, Wei

“…Mutations in and/or (BRCAm), other homologous recombination repair genes (HRRm), and homologous recombination deficiency (HRD) lead to an accumulation of…”
Get more information

One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation by Smith, Jordan L, Lee, Liam C, Read, Abigail, Li, Qiuning, Yu, Bing, Lee, Chih-Shia, Luo, Ji

“…The ability to transform normal human cells into cancer cells with the introduction of defined genetic alterations is a valuable method for understanding the…”
Get full text